LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data

BackgroundWide-ranging placebo responses challenge SLE trials. This analysis aims to identify predictors of SOC+PBO response in patients with SLE.MethodsAnalyses used the SOC+PBO arm of the phase 2b trial of dapirolizumab pegol (NCT02804763), a polyethylene glycol conjugated antigen-binding fragment lacking a functional Fc domain, which inhibits CD40-CD40L interaction.¹ Response was assessed by BILAG-based Composite Lupus Assessment (BICLA) response at Week 24.² Univariate/multivariate analyses were performed, with 22 previously determined potential predictors. Stepwise multivariate analysis included univariate predictors with p